Xeris Biopharma Holdings, Inc. Common Stock XERS
Analyst Ratings
- Consensus
- Buy — 4 Buy · 1 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $12.80 (+46.5% upside)
Key Stats
- Today's Range
- $8.16 – $8.74
- 50-Day Range
- $7.05 – $9.02
- 52-Week Range
- $5.25 – $10.08
- Volume
- 820K shs
- Average Volume
- 1.72 million shs
- Market Cap
- $1.50 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 75.17
- Price / Sales
- 44.79
Short Interest
- Short Interest
- 0.10%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $33.38 million
- Net Income
- $-83,783,000
- Net Margin
- -251.01%
- Return on Equity
- -421.27%
- Debt-to-Equity
- 4.40
About Xeris Biopharma Holdings, Inc. Common Stock
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Related Stocks
Compare head-to-head: XERS vs LLY·XERS vs JNJ·XERS vs ABBV·XERS vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.